Psychosocial and Economic Impact of Cancer

Dental Clinics of North America

Volumn 52, Issue 1, 2008, Pages 231-252

  Elting, Linda S ^a   Avritscher, Elenir B C ^a   Cooksley, Catherine D ^a   Cardenas Turanzas, Marylou ^a   Garden, Adam S ^a   Chambers, Mark S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CHILD; ECONOMICS; FACE PAIN; FAMILY; HEAD AND NECK TUMOR; HEALTH INSURANCE; HUMAN; NEOPLASM; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RADIOTHERAPY; REVIEW; STOMATITIS; SURVIVAL;

ANTINEOPLASTIC AGENTS; CHILD; FACIAL PAIN; FAMILY; HEAD AND NECK NEOPLASMS; HUMANS; INSURANCE, HEALTH; NEOPLASMS; QUALITY OF LIFE; RADIOTHERAPY; STOMATITIS; SURVIVAL ANALYSIS;

EID: 37249093452     PISSN: 00118532     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cden.2007.09.001     Document Type: Review

References (120)

1. Gotay C.C., and Pagano I.S. Assessment of survivor concerns(ASC): a newly proposed brief questionnaire. Health Qual Life Outcomes 5 1 (2007) 15
2. Scott S.E., Grunfeld E.A., and McGurk M. Patient's delay in oral cancer: a systematic review. Community Dent Oral Epidemiol 34 5 (2006) 337-343
3. Wiseman M. The treatment of oral problems in the palliative patient. J Can Dent Assoc 72 5 (2006) 453-458
4. Coates A., Porzsolt F., and Osoba D. Quality of life in oncology practice: prognostic value of EORTC QLQ-C30 scores in patients with advanced malignancy. Eur J Cancer 33 7 (1997) 1025-1030
5. Karnofsky D.A., and Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod C.M. (Ed). Evaluation of chemotherapeutic agents (1949), Columbia University Press 196
6. Osoba D. A taxonomy of the uses of health-related quality-of-life instruments in cancer care and the clinical meaningfulness of the results. Med Care 40 Suppl 6 (2002) III31-III38
7. Dancey J., Zee B., Osoba D., et al. Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. Qual Life Res 6 2 (1997) 151-158
8. Cella D. Manual for the functional assessment of cancer therapy (FACT) measurement system (1993), Rush Medical Center, Chicago
9. Zigmond A.S., and Snaith R.P. The hospital anxiety and depression scale. Acta Psychiatr Scand 67 6 (1983) 361-370
10. Schreurs P.J.G., van de Willige G., Brosschot J.F., et al. GMH: De Utrechtse Coping Lijs: UCL (The Utrecht Coping List) (1993), Swets en Zeitlinger, Lisse (Netherlands)
11. Aaronson N.K., Ahmedzai S., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 5 (1993) 365-376
12. Snyder C.F., Dy S.M., Hendricks D.E., et al. Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice. Support Care Cancer 15 9 (2007) 1075-1085
13. Richardson A., Sitzia J., Brown V., et al. Patients' needs assessment tools in cancer care: principles and practice (2005), King's College London, London
14. Davidson FL Jr, Zetes-Zanatta L, Ram SS, et al. Assessing the supportive care needs of patients who attend a cancer centre: development and feasibility of a questionnaire [abstract]. Presented at the International Society for Quality Of Life Research Conference, Prague (Czech Republic), November 12-15, 2003.
15. Bonevski B., Sanson-Fisher R., Girgis A., et al. Evaluation of an instrument to assess the needs of patients with cancer: Supportive Care Review Group. Cancer 88 1 (2000) 217-225
16. American Cancer Society. Cancer facts & figures 2007. Available at: http://www.cancer.org/downloads/STT/CAFF2007PWSecured.pdf. Accessed March 20, 2007.
17. Langa K.M., Fendrick A.M., Chernew M.E., et al. Out-of-pocket health-care expenditures among older Americans with cancer. Value Health 7 2 (2004) 186-194
18. USA Today/Kaiser Family Foundation/Harvard School of Public Health: Health Care Costs Survey Summary and Chartpack (publication No. 7371) (2005), The Henry J. Kaiser Family Foundation, Menlo Park (CA). http://www.kff.org/newsmedia/7371.cfm Accessed March 20, 2007
19. Kessler R.C., Greenberg P.E., Mickelson K.D., et al. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 43 3 (2001) 218-225
20. Yabroff K.R., Davis W.W., Lamont E.B., et al. Patient time costs associated with cancer care. J Natl Cancer Inst 99 (2007) 14-23
21. Kim P. Cost of cancer care: the patient perspective. J Clin Oncol 25 2 (2007) 228-232
22. National Cancer Institute. Cancer trends progress report-2005 update. Available at: http://progressreport.cancer.gov. Accessed March 23, 2007.
23. Olin GL, Rhoades JA. The five most costly medical conditions, 1997 and 2002: estimates for the U.S. civilian noninstitutionalized population. Statistical Brief No. 80. Rockville (MD): Agency for Healthcare Research and Quality. Available at: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st80/stat80.pdf. Accessed March 15, 2007.
24. Ravasco P., Monteiro-Grillo I., Vidal P.M., et al. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy. Head Neck 27 8 (2005) 659-668
25. Cella D., Pulliam J., Fuchs H., et al. Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. Cancer 98 2 (2003) 406-412
26. Epstein J.B., and Schubert M.M. Management of orofacial pain in cancer patients. Eur J Cancer B Oral Oncol 29B 4 (1993) 243-250
27. Dale R.A., Harrison J.S., and Redding S.W. Oral complications in cancer chemotherapy, cancer incidence, and mortality in the U.S. Gen Dent 52 1 (2004) 64-71 quiz 72
28. Scully C., Sonis S., and Diz P.D. Oral mucositis. Oral Dis 12 3 (2006) 229-241
29. Elting L.S., Cooksley C.D., Chambers M.S., et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68 4 (2007) 1110-1120
30. Sonis S.T., Elting L.S., Keefe D., et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100 Suppl 9 (2004) 1995-2025
31. Trotti A. Toxicity in head and neck cancer: a review of trends and issues. Int J Radiat Oncol Biol Phys 47 1 (2000) 1-12
32. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 3 (2003) 253-262
33. Sonis S.T., and Fey E.G. Oral complications of cancer therapy. Oncology (Williston Park) 16 5 (2002) 680-686
34. Peterman A., Cella D., Glandon G., et al. Mucositis in head and neck cancer: economic and quality-of-life outcomes. J Natl Cancer Inst Monogr 29 (2001) 45-51
35. Vera-Llonch M., Oster G., Hagiwara M., et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer 106 2 (2006) 329-336
36. Garden A.S. Altered fractionation for head and neck cancer. Oncology (Williston Park) 15 10 (2001) 1326-1332
37. Brizel D.M., Wasserman T.H., Henke M., et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18 19 (2000) 3339-3345
38. Bennett C.L., Lane D., Stinson T., et al. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 19 2 (2001) 107-113
39. Calhoun E.A., and Bennett C.L. Pharmacoeconomics of amifostine in ovarian cancer. Semin Oncol 26 2 Suppl 7 (1999) 102-107
40. Clarkson J.E., Worthington H.V., and Eden O.B. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 3 (2003) CD000978
41. Elting L.S., Bodey G.P., and Keefe B.H. Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14 6 (1992) 1201-1207
42. Ruescher T.J., Sodeifi A., Scrivani S.J., et al. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. Cancer 82 11 (1998) 2275-2281
43. Spielberger R., Stiff P., Bensinger W., et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351 25 (2004) 2590-2598
44. Stiff P.J., Emmanouilides C., Bensinger W.I., et al. Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24 33 (2006) 5186-5193
45. Sonis S.T., Oster G., Fuchs H., et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19 8 (2001) 2201-2205
46. Elting L.S., Shih Y.C., Stiff P.J., et al. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trail results. Biol Blood Marrow Transplant 13 7 (2007) 806-813
47. Elting L.S., Cooksley C., Chambers M., et al. The burdens of cancer therapy: clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 98 7 (2003) 1531-1539
48. McElroy T.H. Infection in the patient receiving chemotherapy for cancer: oral considerations. J Am Dent Assoc 109 3 (1984) 454-456
49. Wingard J.R. Oral complications of cancer therapies: infectious and noninfectious systemic consequences. NCI Monogr 9 (1990) 21-26
50. Heimdahl A. Prevention and management of oral infections in cancer patients. Support Care Cancer 7 4 (1999) 224-228
51. Fleming T. Redbook: pharmacy's fundamental reference (2003), Thomson Healthcare, Montvale (NJ)
52. Chambers M.S., Garden A.S., Kies M.S., et al. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 26 9 (2004) 796-807
53. Emami B., Lyman J., Brown A., et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21 1 (1991) 109-122
54. Bussels B., Maes A., Flamen P., et al. Dose-response relationships within the parotid gland after radiotherapy for head and neck cancer. Radiother Oncol 73 3 (2004) 297-306
55. Chambers M.S., Garden A.S., Rosenthal D., et al. Intensity-modulated radiotherapy: is xerostomia still prevalent?. Curr Oncol Rep 7 2 (2005) 131-136
56. Johnston C.A., Keane T.J., and Prudo S.M. Weight loss in patients receiving radical radiation therapy for head and neck cancer: a prospective study. JPEN J Parenter Enteral Nutr 6 5 (1982) 399-402
57. Vissink A., Burlage F.R., Spijkervet F.K., et al. Prevention and treatment of the consequences of head and neck radiotherapy. Crit Rev Oral Biol Med 14 3 (2003) 213-225
58. Roh J.L., Kim A.Y., and Cho M.J. Xerostomia following radiotherapy of the head and neck affects vocal function. J Clin Oncol 23 13 (2005) 3016-3023
59. Davies A.N., Broadley K., and Beighton D. Xerostomia in patients with advanced cancer. J Pain Symptom Manage 22 4 (2001) 820-825
60. Vissink A., Jansma J., Spijkervet F.K., et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 14 3 (2003) 199-212
61. Schuchter L.M., Hensley M.L., Meropol N.J., et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 20 12 (2002) 2895-2903
62. Connor N.P., Cohen S.B., Kammer R.E., et al. Impact of conventional radiotherapy on health-related quality of life and critical functions of the head and neck. Int J Radiat Oncol Biol Phys 65 4 (2006) 1051-1062
63. Rieger J.M., Zalmanowitz J.G., and Wolfaardt J.F. Functional outcomes after organ preservation treatment in head and neck cancer: a critical review of the literature. Int J Oral Maxillofac Surg 35 7 (2006) 581-587
64. Migliorati C.A. Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21 22 (2003) 4253-4254
65. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 9 (2003) 1115-1117
66. Epstein J., van der Meij E., McKenzie M., et al. Postradiation osteonecrosis of the mandible: a long-term follow-up study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 83 6 (1997) 657-662
67. Bamias A., Kastritis E., Bamia C., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 34 (2005) 8580-8587
68. Migliorati C.A., Siegel M.A., and Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 7 6 (2006) 508-514
69. Cleeland C.S. Pain assessment in cancer. In: Obosa D. (Ed). Effects of cancer on quality of life (1991), CRC Press, Boca Raton (FL) 293-305
70. Cleeland C.S., Mendoza T.R., Wang X.S., et al. Assessing symptom distress in cancer patients. Cancer 89 7 (2000) 1634-1646
71. Jones H.A., Hershock D., Machtay M., et al. Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrument. Am J Clin Oncol 29 2 (2006) 158-162
72. Zeine L., and Larson M. Pre- and postoperative counseling for laryngectomies and their spouses: an update. J Commun Disord 32 1 (1999) 51-61 quiz 61-71
73. List M.A., D'Antonio L.L., Cella D.F., et al. The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale: a study of utility and validity. Cancer 77 11 (1996) 2294-2301
74. de Leeuw J.R., de Graeff A., Ros W.J., et al. Prediction of depression 6 months to 3 years after treatment of head and neck cancer. Head Neck 23 10 (2001) 892-898
75. van Bokhorst-de van der S., van Leeuwen P.A., Kuik D.J., et al. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer 86 3 (1999) 519-527
76. Sherman A.C., Simonton S., Adams D.C., et al. Assessing quality of life in patients with head and neck cancer: cross-validation of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Head and Neck module (QLQ-H&N35). Arch Otolaryngol Head Neck Surg 126 4 (2000) 459-467
77. Petruson K.M., Silander E.M., and Hammerlid E.B. Quality of life as predictor of weight loss in patients with head and neck cancer. Head Neck 27 4 (2005) 302-310
78. D'Antonio L.L., Zimmerman G.J., Cella D.F., et al. Quality of life and functional status measures in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 122 5 (1996) 482-487
79. Ries LAG, Melbert D, Krapcho M, et al, editors. SEER cancer statistics review, 1975-2004. Available at: http://seer.cancer.gov/csr/1975_2004/. Accessed May 22, 2007.
80. Happ M.B., Roesch T., and Kagan S.H. Communication needs, methods, and perceived voice quality head and neck surgery: a literature review. Cancer Nurs 26 5 (2003) 346-354
81. Holloway R.L., Hellewell J.L., Marbella A.M., et al. Psychosocial effects in long-term head and neck cancer survivors. Head Neck 27 4 (2005) 281-288
82. Taylor J.C., Terrell J.E., Ronis D.L., et al. Disability in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 130 6 (2004) 764-769
83. U.S. Department of Labor. Bureau of Labor Statistics. Consumer Price Indexes. Available at: http://www.bls.gov/cpi/home.htm. Accessed April 12, 2007.
84. Brown M.L., Riley G.F., Schussler N., et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 40 Suppl 8 (2002) 104-117
85. Lee J.M., Turini M., Botteman M.F., et al. Economic burden of head and neck cancer: a literature review. Eur J Health Econ 5 1 (2004) 70-80
86. Lang K., Menzin J., Earle C.C., et al. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data. Arch Otolaryngol Head Neck Surg 130 11 (2004) 1269-1275
87. Cronin K., Lee B., and Wang D. Cost of treatment for squamous cell carcinoma of the head and neck in the United States. Value Health 4 (2001) 94
88. Cozzi L., and Fogliata A. IMRT in the treatment of head and neck cancer: is the present already the future?. Expert Rev Anticancer Ther 2 3 (2002) 297-308
89. Grant III W., and Woo S.Y. Clinical and financial issues for intensity-modulated radiation therapy delivery. Semin Radiat Oncol 9 1 (1999) 99-107
90. American Cancer Society. Oral cancer. Available at: http://www.cancer.org/downloads/PRO/OralCancer.pdf. Accessed April 5, 2007.
91. Brown M.L., Hodgoson T.A., and Rice D.P. Economic impact of cancer in the United States. In: Schottenfeld D., and Fraumeni J. (Eds). Cancer epidemiology and prevention (1993), Oxford University Press, New York 255-266
92. Shiboski C.H., Schmidt B.L., and Jordan R.C. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years. Cancer 103 9 (2005) 1843-1849
93. Margolin J.F., Poplack D.G., Pizzo P.A., et al. Acute lymphoblastic leukemia. In: Pizzo P., and Poplack D. (Eds). Principles and practice of pediatric oncology (2002), Lippincott, Williams & Wilkins, Philadelphia 409-462
94. Pui C.H. Pediatric oncology: acute lymphoblastic leukemia. Pediatr Clin North Am 44 (1997) 831-846
95. da Fonseca M.A. Dental care of the pediatric cancer patient. Pediatr Dent 26 1 (2004) 53-57
96. Mash E., and Lloyd-Williams M. A survey of the services provided by children's hospices in the United Kingdom. Support Care Cancer 14 12 (2006) 1169-1172
97. Wijnberg-Williams B.J., Kamps W.A., Klip E.C., et al. Psychological adjustment of parents of pediatric cancer patients revisited: five years later. Psychooncology 15 1 (2006) 1-8
98. Nolbris M., Enskar K., and Hellstrom A.L. Experience of siblings of children treated for cancer. Eur J Oncol Nurs 11 2 (2007) 106-112
99. Howe H.L., Wu X., Ries L.A., et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer 107 8 (2006) 1711-1742
100. In: Ries L.G., Smith M.A., Gurney J.F., et al. (Eds). Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995 (1999), National Institute of Health, Bethesda (MD) NIH Pub. No. 99-4649
101. Oeffinger K.C., Mertens A.C., Sklar C.A., et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355 15 (2006) 1572-1582
102. Kaste S.C., Hopkins K.P., Bowman L.C., et al. Dental abnormalities in children treated for neuroblastoma. Med Pediatr Oncol 30 1 (1998) 22-27
103. Denys D., Kaste S.C., Kun L.E., et al. The effects of radiation on craniofacial skeletal growth: a quantitative study. Int J Pediatr Otorhinolaryngol 45 1 (1998) 7-13
104. Kufe D.W., Holland J.F., Frei E., et al. Cancer medicine 6. 6th edition (2003), BC Decker, Hamilton (Ont)
105. Shaw M.J., Kumar N.D., Duggal M., et al. Oral management of patients following oncology treatment: literature review. Br J Oral Maxillofac Surg 38 5 (2000) 519-524
106. Oneschuk D., Hanson J., and Bruera E. A survey of mouth pain and dryness in patients with advanced cancer. Support Care Cancer 8 5 (2000) 372-376
107. McGuire D.B. Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer 11 7 (2003) 435-441
108. Hays D.M. Adult survivors of childhood cancer: employment and insurance issues in different age groups. Cancer 71 Suppl 10 (1993) 3306-3309
109. Bradley C.J. The need for online information on the economic consequences of cancer diagnosis, treatment, and survivorship. J Med Internet Res 7 3 (2005) e29
110. CEO Roundtable on Cancer I. The CEO Gold Standard Implementation workbook. 2005. Available at: http://www.cancergoldstandard.org/accreditation/workbook.pdf. Accessed February 7, 2007.
111. US Department of Health and Human Services, National Cancer Institute. President's Cancer Panel 2005-2006 annual report. Available at: http://deainfo.nci/gov/ADVISORY/pcp/pcp06rpt.pdf. Accessed March 19, 2007.
112. National Coalition for Cancer Survivorship. Cancer doctors and patient groups join initiative to improve quality of care for people with cancer. Available at: http://www.canceradvocacy.org/news/press/2005/cancer-doctors-and-patient.html. Accessed March 19, 2007.
113. Carver C.S., Scheier M.F., and Weintraub J.J. Assessing coping strategies: a theoretically based approach. Journal of Personality and Social Psychology 56 (1989) 267-283
114. McNair D.M., and Lorr M. An analysis of mood in neurotics. Journal of Abnormal and Social Psychology 69 (1964) 620-627
115. McNair D.M., Lorr M., and Droppleman L.F. Manual for the profile of mood states (POMS) (1971), Educational and Industrial Testing Service, San Diego, CA
116. Horowitz M., Wilner M., and Alvarez W. Impact of event scale: a measure of subjective stress. Psychosomatic Medicine 41 (1979) 209-218
117. Van Sonderen E. The measurement of social support (1991), University Press, Groningen, The Netherlands
118. Kempen G.I.J.M., and Van Eijk L.M. The psychometric properties of the SSL12-I, a short scale for measuring social support in the elderly. Soc Indic Res 35 3 (1995) 303-312
119. Pruyn J.F., Borne H.W., Reuver R.S., et al. De locus of control-schaal voor kankerpatienten. T Soc Gezondsheidsz 66 (1988) 404-408
120. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1 (1977) 385-401